Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients

Purpose: To compare survivals between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients receiving first-line EGFR-TKI. Materials and methods: Unresectable stage III and stage IV EGFR-mutated NSCLC patients were investigated from September 2012 to May 2022....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Liang, Huan-Wei, Pan, Xin-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292882/
https://www.ncbi.nlm.nih.gov/pubmed/37294545
http://dx.doi.org/10.18632/aging.204781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292882/
https://www.ncbi.nlm.nih.gov/pubmed/37294545
http://dx.doi.org/10.18632/aging.204781

Ejemplares similares